HK1243079A1 - 水溶性前藥 - Google Patents
水溶性前藥Info
- Publication number
- HK1243079A1 HK1243079A1 HK18102727.6A HK18102727A HK1243079A1 HK 1243079 A1 HK1243079 A1 HK 1243079A1 HK 18102727 A HK18102727 A HK 18102727A HK 1243079 A1 HK1243079 A1 HK 1243079A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- water
- soluble prodrugs
- prodrugs
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139077P | 2015-03-27 | 2015-03-27 | |
| PCT/IB2016/051706 WO2016157052A1 (en) | 2015-03-27 | 2016-03-25 | Water-soluble prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1243079A1 true HK1243079A1 (zh) | 2018-07-06 |
Family
ID=55650622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18102727.6A HK1243079A1 (zh) | 2015-03-27 | 2018-02-26 | 水溶性前藥 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10183925B2 (zh) |
| EP (1) | EP3274346A1 (zh) |
| JP (3) | JP6630364B2 (zh) |
| CN (1) | CN107660202B (zh) |
| CA (1) | CA2980845A1 (zh) |
| HK (1) | HK1243079A1 (zh) |
| TW (1) | TWI710555B (zh) |
| WO (1) | WO2016157052A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6630364B2 (ja) | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル， インコーポレイテッド | 水溶性プロドラッグ |
| US10738023B2 (en) | 2016-03-25 | 2020-08-11 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| EP3686182A4 (en) * | 2017-09-22 | 2021-06-09 | Sumitomo Dainippon Pharma Co., Ltd. | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG |
| WO2022003181A1 (fr) * | 2020-07-03 | 2022-01-06 | Nanotracks Diagnostics | Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée |
| FR3112145A1 (fr) * | 2020-07-03 | 2022-01-07 | Nanotracks Diagnostics | Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations |
| CN112194598B (zh) * | 2020-10-15 | 2021-12-21 | 郑州猫眼农业科技有限公司 | 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732055B2 (en) | 2007-09-10 | 2017-08-15 | Boston Biomedical, Inc. | Compositions and methods for cancer treatment |
| CN103402993A (zh) * | 2011-03-04 | 2013-11-20 | 舟山海中洲新生药业有限公司 | 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯 |
| WO2013120229A1 (en) | 2012-02-17 | 2013-08-22 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| JP6630364B2 (ja) * | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル， インコーポレイテッド | 水溶性プロドラッグ |
-
2016
- 2016-03-25 JP JP2017549601A patent/JP6630364B2/ja not_active Expired - Fee Related
- 2016-03-25 CN CN201680030052.0A patent/CN107660202B/zh not_active Expired - Fee Related
- 2016-03-25 WO PCT/IB2016/051706 patent/WO2016157052A1/en active Application Filing
- 2016-03-25 CA CA2980845A patent/CA2980845A1/en not_active Abandoned
- 2016-03-25 US US15/561,828 patent/US10183925B2/en active Active
- 2016-03-25 TW TW105109636A patent/TWI710555B/zh not_active IP Right Cessation
- 2016-03-25 EP EP16714015.1A patent/EP3274346A1/en not_active Ceased
-
2018
- 2018-02-26 HK HK18102727.6A patent/HK1243079A1/zh unknown
- 2018-11-19 US US16/194,525 patent/US10800752B2/en active Active
-
2019
- 2019-12-06 JP JP2019221478A patent/JP6885999B2/ja active Active
-
2020
- 2020-08-28 US US17/005,597 patent/US11414394B2/en active Active
-
2021
- 2021-05-13 JP JP2021081570A patent/JP2021120401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016157052A1 (en) | 2016-10-06 |
| US20180111914A1 (en) | 2018-04-26 |
| JP2018509441A (ja) | 2018-04-05 |
| US20200392098A1 (en) | 2020-12-17 |
| CN107660202A (zh) | 2018-02-02 |
| TW201639824A (zh) | 2016-11-16 |
| US11414394B2 (en) | 2022-08-16 |
| JP2020055854A (ja) | 2020-04-09 |
| CA2980845A1 (en) | 2016-10-06 |
| TWI710555B (zh) | 2020-11-21 |
| US20190084955A1 (en) | 2019-03-21 |
| CN107660202B (zh) | 2021-12-24 |
| EP3274346A1 (en) | 2018-01-31 |
| JP6630364B2 (ja) | 2020-01-15 |
| US10183925B2 (en) | 2019-01-22 |
| US10800752B2 (en) | 2020-10-13 |
| JP6885999B2 (ja) | 2021-06-16 |
| JP2021120401A (ja) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3394080C0 (en) | LIPID-LINKED PRODRUGS | |
| IL248642A0 (en) | Gemcitabine drug inhibitors | |
| HK1243079A1 (zh) | 水溶性前藥 | |
| HK1247576A1 (zh) | 氧雜二環庚烷前藥 | |
| AU361999S (en) | Ballustrade | |
| PT3360866T (pt) | Pró-fármacos de mirabegrom | |
| GB201521215D0 (en) | Prodrug | |
| GB201708458D0 (en) | Prodrugs | |
| GB201516577D0 (en) | Project P | |
| GB201516735D0 (en) | Patent Forms | |
| GB201520667D0 (en) | It | |
| GB201520360D0 (en) | It | |
| GB201520282D0 (en) | It | |
| GB201519595D0 (en) | It | |
| GB201519507D0 (en) | it | |
| GB201519371D0 (en) | It | |
| GB201519278D0 (en) | It | |
| GB201518920D0 (en) | It | |
| GB201518772D0 (en) | It | |
| GB201518610D0 (en) | It | |
| GB201518696D0 (en) | It | |
| GB201518487D0 (en) | It | |
| GB201518484D0 (en) | It | |
| GB201518490D0 (en) | It | |
| GB201518491D0 (en) | It |